Group 1: Financial Impact and Performance - The company does not engage in cochlear implant business, and the net profit from its investment in Beijing Zhongyi Technology Co., which focuses on hearing aids and cochlear implant consulting, accounts for less than 1% of total net profit, indicating no significant impact from the national procurement of cochlear implants on revenue and profit [2] - In Q3 2024, the company's revenue reached 43.93 million CNY, a 61.61% increase compared to Q2, suggesting positive momentum for future revenue growth [4] Group 2: Strategic Acquisitions and Market Position - The acquisition of IntriCon Inc. and its related hearing health assets is expected to enhance the company's core technology in hearing aids, particularly in algorithms, and facilitate self-sufficiency in mid-to-high-end hearing aid chips [2] - The company aims to leverage the acquired technology to improve product competitiveness in the OTC market [5] Group 3: International Expansion - The company has established a subsidiary, Audicon Corporation, in the U.S. in 2022, focusing on online product operations, with steady sales growth on platforms like Amazon [3] - The company has obtained EU MDR certification and is expanding its market presence in Europe, while also pursuing MDSAP certification in Japan to enhance product distribution [3] Group 4: Future Development and R&D Focus - Future R&D investments will concentrate on three areas: continuous development of hearing aid chips and algorithms, professional fitting of hearing aids for direct sales and distribution networks, and high-end OTC product development using technology from IntriCon Inc. [5] - The company is currently focusing on steady expansion of its self-operated hearing centers primarily in the Greater Bay Area, with plans to adapt to market changes for potential expansion into other regions [3]
锦好医疗(872925) - 关于投资者关系活动记录表的公告